Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | THPO | P40225 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | APEX1 | P27695 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608299 | 0.82 | MAPT (0.48) | HSD17B10KDM4EMAPTHPGDTDP1 | |
| SCHEMBL1396565 | 0.82 | HSD17B10 (0.64) | HSD17B10KDM4EMAPTHPGDTDP1 | |
| SCHEMBL12608328 | 0.81 | ALDH1A1 (0.43) | ALDH1A1POLBSMN1; SMN2GAA | |
| SCHEMBL11533258 | 0.80 | HSD17B10 (0.65) | HSD17B10KDM4EMAPTHPGDTDP1 | |
| SCHEMBL10777945 | 0.77 | KDM4E (0.54) | HSD17B10KDM4EMAPTHPGDTDP1 | |
| SCHEMBL11534896 | 0.71 | HSD17B10 (0.60) | HSD17B10KDM4EMAPTHPGDTDP1 | |
| SCHEMBL339753 | 0.70 | ERCC1 (0.59) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| Methyldopa SCHEMBL11427795 | 0.70 | KDM4E (0.88) | HSD17B10KDM4EMAPTHPGDTDP1 | |
| SCHEMBL30446328 | 0.69 | MAPT (0.73) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL27762142 | 0.69 | HSD17B10 (0.67) | HSD17B10KDM4EMAPTHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404760-B2 | Filled dental material based on polymerizable dihydroxy-phenylalanine derivatives | IVOCLAR VIVADENT AG (LI) | 2013-03-26 | — | — | US | disclosed |
| US-8404760-B2 | Filled dental material based on polymerizable dihydroxy-phenylalanine derivatives | IVOCLAR VIVADENT AG (LI) | 2013-03-26 | — | — | US | disclosed |
| EP-2324810-A1 | Filled dental material based on polymerisable dihydroxyphenylalanine derivatives | Ivoclar Vivadent AG (LI) | 2011-05-25 | — | — | EP | disclosed |
| US-20110118380-A1 | Filled Dental Material Based on Polymerizable Dihydroxy-Phenylalanine Derivatives | IVOCLAR VIVADENT AG (LI) | 2011-05-19 | — | — | US | disclosed |
| US-20110118380-A1 | Filled Dental Material Based on Polymerizable Dihydroxy-Phenylalanine Derivatives | IVOCLAR VIVADENT AG (LI) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118380-A1 | Filled Dental Material Based on Polymerizable Dihydroxy-Phenylalanine Derivatives | PAH, FANCI, P4HA1 | HSD17B10 439/4885KDM4E 1100/4885MAPT 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.